Bulanta™
Conditioning agent for stem cell transplantation in Chronic Myelogenous Leukemia (CML)
Pre-NDAActive
Key Facts
Indication
Conditioning agent for stem cell transplantation in Chronic Myelogenous Leukemia (CML)
Phase
Pre-NDA
Status
Active
Company
About GreenJay Therapeutics
GreenJay Therapeutics is a private, pre-revenue biotech founded in 2022, developing a safer IV formulation of busulfan called Bulanta™. The technology aims to replace current solvent-laden formulations, potentially reducing patient toxicity while maintaining efficacy in chronic myeloid leukemia (CML) and other stem cell transplant settings. The company has completed key manufacturing milestones and a Series A financing round, positioning it for late-stage regulatory filings.
View full company profile